In particular, the identification of mutations in the gene encoding epidermal growth factor receptor (EGFR) in NSCLC patients with adenocarcinoma has led to the utilization of small-molecule tyrosine kinase inhibitors, such as gefitinib or afatinib specifically for that subtype of patients (11). The gene discussed is EGFR; the disease is adenocarcinoma.